Elisabetsky E, Costa-Campos L
Departamento de Farmacologia, UFRGS, Porto Alegre, Brazil.
J Ethnopharmacol. 1996 Apr;51(1-3):111-9; discussion 119-20. doi: 10.1016/0378-8741(95)01353-9.
Brazil is a gene rich country, host to 24% of known primate species, between 10 and 15 million species of insects, and 22% of the world's higher plant species. The debate over how and by whom these resources should be protected has intensified over the last few years due to a growing awareness of the links between sustainable utilization of natural resources, conservation of biodiversity, and economic development. Within this context the pharmaceutical exploitation of natural products for drug development has a prominent place. For a significant portion of Brazilian society, fair cooperation is welcome and can facilitate drug discovery. Nevertheless, the complexity of the consequences of patenting and utilization of natural resources calls for a thorough cost/benefit analysis in order to promote policies that can ensure significant and long term benefits for the country.
巴西是一个基因资源丰富的国家,拥有已知灵长类物种的24%、1000万至1500万种昆虫,以及世界上22%的高等植物物种。在过去几年里,由于人们越来越意识到自然资源的可持续利用、生物多样性保护和经济发展之间的联系,关于这些资源应如何保护以及由谁来保护的争论愈演愈烈。在此背景下,天然产物在药物开发中的药用价值备受瞩目。对于很大一部分巴西社会群体而言,公平合作是受欢迎的,并且能够推动药物研发。然而,自然资源专利和利用所带来后果的复杂性要求进行全面的成本效益分析,以制定能够确保该国获得重大长期利益的政策。